BSX vs COO
BSX: Boston Scientific is a leading medical technology company delivering minimally invasive interventional solutions to improve patient health across diverse clinical specialties. COO: A global medical device leader operating at the intersection of vision care and women's health through its CooperVision and CooperSurgical divisions.
Side-by-side fundamentals
| Metric | BSX | COO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $42.97 | $70.50 | |
| Market cap as of 2026-07-23 | $63.7B | $13.9B | |
| P/E as of 2026-07-23 | 17.88 | 58.76 | BSX lower |
| PEG as of 2026-07-23 | 0.24 | 6.73 | BSX lower |
| Net margin as of 2026-07-23 | +17.3% | +5.6% | BSX higher |
| Gross margin as of 2026-07-23 | +69.1% | +65.5% | BSX higher |
| Operating margin as of 2026-07-23 | +18.4% | +11.8% | BSX higher |
| ROE as of 2026-07-23 | +14.9% | +2.8% | BSX higher |
| ROA as of 2026-07-23 | +8.3% | +1.9% | BSX higher |
| Debt / equity as of 2026-07-23 | 0.43 | 0.30 | COO lower |
| Revenue growth (YoY) as of 2026-07-23 | +17.4% | +6.1% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +7.3% | BSX higher |
| Dividend yield as of 2026-07-23 | +0.0% | +0.0% | COO higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.58 | 0.82 | |
| 1-year return as of 2026-07-22 close | -58.3% | -3.5% | COO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.